Purpose: To assess the relationship between plasma homocysteine levels and restenosis after femoropopliteal percutaneous transluminal angioplasty. Methods: Over a 10-month period, 128 consecutive, symptomatic patients (72 men; median age 70 years) having successful femoropopliteal angioplasty for atherosclerotic occlusive disease were prospectively enrolled in the study. Plasma homocysteine levels were determined the day before the procedure. The primary endpoint was restenosis Ͼ50%, documented by duplex sonography, at up to 12 months' follow-up. Cox proportional hazards analysis was used to determine the risk of restenosis in relation to pretreatment homocysteine levels. Results: The restenosis rate at 12 months was 46%. Median baseline plasma homocysteine levels were not different in patients with and without restenosis (15.4 versus 16.7 mol/L, pϭ0.30). Compared to patients with homocysteine levels Յ14 mol/L (lower tertile, nϭ43), the hazard ratio of incident restenosis was 0.75 (95% CI 0.40 to 1.40) in patients with homocysteine levels from 14.1 to 19.6 mol/L (middle tertile, nϭ42) and 0.64 (95% CI 0.33 to 1.22) in patients with homocysteine levels Ն19.7 mol/L (upper tertile, nϭ42) (pϭ0.38). Multivariate analysis showed that lesion length (pϽ0.0001) and lack of hypertension (pϭ0.0013) were associated with restenosis. Conclusions: Elevated plasma homocysteine levels are not associated with restenosis after femoropopliteal angioplasty. Therefore, plasma homocysteine cannot be considered as an important risk factor influencing the outcome after initially successful angioplasty in femoropopliteal arteries.
Restenosis remains a major problem after initially successful angioplasty, occurring in 35% to 50% of lower limb arteries within 1 year after the initial angioplasty procedure. [1] [2] [3] [4] [5] Thus, by necessitating further interventions, restenosis has not only clinical but also economical implications.
The mechanisms of restenosis are complex and still not completely understood. Restenosis is most commonly secondary to myointimal proliferation, arterial remodeling, and/ or platelet deposition with subsequent release of platelet derived growth factor. [6] [7] [8] [9] [10] [11] Many mediators are related to these patho-physiological mechanisms and contribute to the development of restenosis after angioplasty of peripheral arteries. One of these mediators, hyperhomocysteinemia, is now an accepted and potentially modifiable risk factor for cardiovascular disease and death. [12] [13] [14] [15] Because endothelial cell damage, vascular smooth muscle cell (SMC) proliferation, and thrombus formation after angioplasty could be influenced by homocysteine, hyperhomocysteinemia might affect the outcome after percutaneous transluminal angioplasty. Although a significant association between hyperhomocysteinemia and outcome after coronary angioplasty has been reported, [16] [17] [18] [19] the relationship between hyperhomocysteinemia and restenosis after initially successful angioplasty of peripheral arteries has not yet been thoroughly investigated. In the present study, we sought to evaluate whether pretreatment plasma homocysteine levels are related to outcome after femoropopliteal angioplasty.
METHODS

Study Design
In a prospective study conducted in accordance with the recommendations of the Declaration of Helsinki and approved by the local ethics committee, symptomatic patients with angiographically or sonographically documented femoropopliteal Ͼ50% de novo or recurrent lesions were enrolled if primary femoropopliteal angioplasty (with or without local thrombolysis and/or thrombus extraction) was successful. Patients were excluded (1) if they were taking anticoagulants or medication that affects the homocysteine pathway (multivitamins, tricyclic antidepressants, carbamazepine, levodopa, or phenytoin); (2) when stent implantation was necessary; (3) if nonatherosclerotic vascular disease was present; (4) if the lesion was in a femoropopliteal bypass graft; (5) when additional interventions were performed during follow-up; or (6) if the life expectancy was Ͻ12 months.
Angioplasty was performed with standard guidewires and balloon catheters; balloon pressure and inflation duration were left to the discretion of the operator. A successful procedure was defined as Յ30% residual ste-nosis documented by duplex sonography the day after the procedure. 20, 21 Patients were given 100 mg/d of aspirin starting at least the day before the procedure if they were not already on aspirin therapy. Adjunctive drug therapy (e.g., unfractionated or low-molecular-weight heparin, locally applied urokinase) was also at the discretion of the operator.
Patient Sample
Over a 10-month period, 128 consecutive patients (72 men; median age 70 years) were enrolled and gave written informed consent to participate in the study. At entry, the patient's age, sex, and vascular risk factors (diabetes, hyperlipidemia, hypertension, smoking habits) were recorded, as was current medication. The patient's self-reported history was taken, followed by a clinical examination (palpation of peripheral pulses, auscultation of bruits) and noninvasive assessment, including pulse volume recordings, and ankle systolic pressure measurements for calculation of the ankle-brachial index (ABI) at rest. The severity of peripheral arterial occlusive disease was classified using Fontaine stage II (claudication) or stage III/IV (critical limb ischemia with persistently recurrent pain requiring regular analgesia for Ͼ2 weeks and/ or ulceration or gangrene of the foot or toes plus ankle systolic pressure Ͻ50 mmHg). Characteristics of the lesions to be treated (stenosis/occlusion) were recorded as documented by angiography.
Plasma Homocysteine and Other Laboratory Tests
Fasting venous blood samples were drawn early on the day before intervention and processed immediately. Total plasma homocysteine levels were determined using a chemiluminescence enzyme immunoassay (ImmuLight 2000; Diagnostic Products Corp., Los Angeles, CA, USA). Additional routine blood tests included measurement of creatinine, cholesterol (HDL, LDL), triglycerides, glycosylated hemoglobin, hematocrit, platelets, and leukocytes using standard established laboratory methods.
Follow-up and Endpoints
Patients were assessed the day after the procedure and at 1, 3, 6, and 12 months by taking the history, clinical examination (palpation of peripheral pulses, auscultation of bruits), pulse volume recordings, ankle systolic pressure measurement for calculation of the ABI. The day after the procedure and at 3, 6, and 12 months, color-coded duplex sonography of the treated femoropopliteal segment was performed with a 5-MHz linear probe (Acuson XP10; Siemens, Mountain View, CA, USA). Duplex was also performed at any time during follow-up when restenosis/reocclusion was suspected due to symptomatology, clinical examination, and/or a Ͼ0.15 decrease in the ABI from the postprocedural value. Peak systolic velocities (PSV) in the treated segment and in the proximal normal segment were measured, and peak velocity ratio (PVR: PSV in the dilated segment divided by the proximal PSV) was calculated. A PVR Ն2.4 indicated a significant (Ն50%) restenosis at that site. 21 The primary endpoint was restenosis Ͼ50% demonstrated by duplex sonography at up to 12 months. The secondary endpoint was clinical outcome defined as recurrent or increased symptoms.
Statistical Analysis
The calculation of an appropriate sample size was based on the following statement: if the probability for a patient with restenosis to have a higher level of homocysteine than a patient without restenosis is Ͼ0.65, a significant difference between the groups will be detected in Ͼ80% of the cases if both groups contain at least 60 patients.
StatView 5.0 (Abacus Concepts, SAS Institute, Cary, NC, USA) was used for data management and analyses. Homocysteine was examined as a continuous variable and as a dichotomous variable in tertiles. Continuous variables are reported as medians and interquartile ranges, categorical variables as counts and percentages. Intergroup comparisons of baseline data were done using the Wilcoxon rank sum test for continuous variables and the Fisher exact test for categorical variables. Differences between the groups according to homocysteine tertiles were tested using the Kruskal-Wallis test for continuous variables and the chi-square test for categorical variables. Freedom from restenosis according to homocysteine in tertiles was plotted as Kaplan-Meier curves; differences among the groups were analyzed by the logrank test.
Cox proportional hazard analysis was used to determine an association between restenosis and homocysteine in tertiles, expressing the results as the hazard ratio (HR) with 95% confidence interval (CI). Multivariate analysis (stepwise backward) was performed to take into account the effect of possible confounders. All variables that showed baseline imbalances (pϽ0.1) between patients with and without restenosis or according to homocysteine tertiles were included in the multivariate model. Significance was defined as pϽ0.05.
RESULTS
Over a median 10-month follow-up (IQR 5-12), 7 (5.5%) patients were lost: 1 at 1 month, 2 at 3 months, 1 at 6 months, and 3 at 12 months. Of those, 1 died of myocardial infarction, 2 refused follow-up, and no information could be obtained on the remaining 4. Thus, complete hemodynamic information by ABI measurements and duplex sonography was available for analysis in 121 patients. Baseline characteristics of the patients lost to follow-up did not differ from patients who continued throughout the study.
Nearly half (56, 46%) of the 121 patients had restenosis documented by duplex sonography at 12 months. Of these, 43 (35%) presented with new onset or increased symptoms; 50 patients had a drop in ABI, but 6 had no clinical symptoms or decrease in ABI. Patients with restenosis had longer lesions and a lower ABI at baseline; occlusion was more frequent than stenosis (Table 1) . Hypertension was less common in patients with restenosis than in those without restenosis. Pretreatment homocysteine levels were not different in patients with and without restenosis. Intake of clopidogrel was more frequent in the restenosis group (11 [19%] no differences between the groups concerning other concomitant medication at discharge (ACE inhibitors, angiotensin receptor blockers, beta blockers, statins, oral antidiabetic agents, insulin, diuretics, allopurinol). All patients were on aspirin. Analysis of baseline characteristics according to homocysteine levels ( Table 2) found that patients in the upper tertile (Ն19.7 mol/ L) had the worse runoff and higher total cholesterol, LDL-cholesterol, and creatinine values than patients in the middle (14.1 to 19.6 mol/L) or lower (Յ14 mol/L) tertiles. However, these third-tertile patients had the lowest rate of restenosis according to the Kaplan-Meier analysis (Fig. 1 ), but the differences among the groups were not statistically significant (pϭ0.35). The hazard ratios (95% CI) of incident restenosis for homocysteine values in tertiles (lower, middle, upper) as estimated by the univariate Cox proportional hazards model was 1.0, 0.75 (0.40-1.40), and 0.64 (0.33-1.22) (pϭ0.38). Multivariate analysis (Table 3) showed that lesion length (pϽ0.0001) and lack of hypertension (pϭ0.0013) were associated with restenosis.
The analysis of hemodynamic outcome (represented by ABI measurements) to homocysteine in tertiles (Fig. 2) showed no difference among the groups in the median ABI at baseline (pϭ0.49; Table 2 ). After the procedure, the ABI (95% CI) rose in all 3 groups: 
DISCUSSION
Several studies have shown that elevated plasma homocysteine is an independent risk factor for the development of atherosclerosis in the coronary, cerebral, and peripheral vas- 
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Ankle-brachial indices (ABI) after femoropopliteal angioplasty with respect to homocysteine levels (in tertiles). culature 12, 13 and is a strong predictor of restenosis after coronary angioplasty. 16, 17 Since homocysteine promotes SMC proliferation, arterial remodeling, and platelet deposition, all of which are involved in the cascade of pathogenic mechanisms leading to restenosis after catheter-based interventions, we hypothesized that elevated plasma homocysteine levels could also be predictive of postangioplasty restenosis in the peripheral vessels. Surprisingly, our prospective study found no such association between baseline plasma homocysteine levels and restenosis after femoropopliteal angioplasty over at 12-month observation period.
In an earlier work, Tsakiris and coworkers 11 presented the same lack of association between preangioplasty homocysteine levels and outcome during a 6-month follow-up. Their study, done in a smaller number of patients over a shorter follow-up than ours, had been designed to investigate the relationship between cell adhesion molecules and outcome after angioplasty. However, no correla-tion between homocysteine and those activation markers was found. Our study, on the other hand was designed specifically to associate pretreatment plasma homocysteine levels with outcome after femoropopliteal angioplasty in a larger cohort.
The surprising divergence in our results for peripheral angioplasty compared to coronary interventions might possibly be explained by differences in the pathophysiological mechanisms underlying atherosclerosis in general and restenosis in particular in the coronary versus femoropopliteal arteries. Increasing evidence suggests that adverse vascular effects of homocysteine are mainly mediated through impaired endothelium-dependent, nitric oxide-mediated vasodilation. 22, 23 An anatomical heterogeneity of endothelial dysfunction has been shown in the setting of vascular aging using a mammalian model. 24 If the same mechanism were applicable to humans, then these anatomical variations may, at least partly, account for the differences observed between peripheral and coronary angioplasty regarding the potential underlying harmful effects of hyperhomocysteinemia. This explanation is further strengthened by the fact that most patients undergoing angioplasty in our study were older.
The exact mechanism of hyperhomocysteinemia-induced endothelial dysfunction is still not completely understood. However, it has been suggested that increased oxidative damage might be involved. 25 In most patients, folic acid alone or in combination with vitamin B 6 and B 12 has been shown to be effective in reducing homocysteine plasma concentrations 26 and to effectively reduce oxidative stress markers. 27 Although folate treatment to lower plasma levels of homocysteine has previously been shown to significantly reduce the rate of restenosis after coronary angioplasty, 18 one may question whether the association of high homocysteine levels and greater incidence of restenosis after coronary angioplasty reflects causality. Folic acid may also exert its beneficial effects through mechanisms independent of homocysteine lowering. However, if hyperhomocysteinemia were to be causally involved, then, based on our current data, its treatment will be of no effect in the setting of peripheral angioplasty.
A limitation of our study is its focus on patients with primarily successful angioplasty; patients with dilation failure or stent implantation, who might have more extensive disease, were excluded. Further limitations are the small sample size and the lack of homocysteine data during follow-up. However, homocysteine values at 12 months were available in a small subgroup of patients (nϭ30): analyzing these data, we found no difference between homocysteine levels at baseline and at 12 months; furthermore, we found no difference in homocysteine levels at 12 months between patients without and with restenosis.
In conclusion, our data suggest that elevated plasma homocysteine levels are not associated with restenosis after femoropopliteal angioplasty. Therefore, therapies solely designed to reduce plasma homocysteine levels will be useless in this particular pathophysiological context.
